Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations

Published:2022-07-13 Issue:5 Volume:149 Page:2029-2039
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Zhuo Xiaoli,Guo Honglin,Ma Jun,Lai Jingjiang,Liu Lei,Yin Ke,Zhao Jing,Wang Jingliang,Jiang Fengxian,Xu Wei,Yuan Xiaotian,Lin Xiaoyan,Fu Guobin^ORCID

Funder

National Natural Science Foundation of China

Taishan Scholar Foundation of Shandong Province

Science and Technology Development Plans of Shandong Province

Clinical Research Fund of Shandong Provincial Medical Association

Scientific Research Foundation of Shandong Province of Outstanding Young Scientists

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04196-7.pdf

Reference28 articles.

1. Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18:4910–4918. https://doi.org/10.1158/1078-0432.CCR-12-0912

2. Auliac JB, Do P, Bayle S et al (2019a) Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02–14. Adv Ther 36:2161–2166. https://doi.org/10.1007/s12325-019-01001-9

3. Auliac JB, Dô P, Bayle S et al (2019b) Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02–14. Adv Ther 36:2161–2166. https://doi.org/10.1007/s12325-019-01001-9

4. Bu S, Wang R, Pan Y et al (2017) Clinicopathologic characteristics of patients with HER2 insertions in non-small cell lung cancer. Ann Surg Oncol 24:291–297. https://doi.org/10.1245/s10434-015-5044-8

5. De Greve J, Moran T, Graas MP et al (2015) Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 88:63–69. https://doi.org/10.1016/j.lungcan.2015.01.013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3